Specification of Drug Substances and Products : Development and Validation of Analytical Methods

Riley, Christopher M. (EDT); Rosanske, Thomas W. (EDT); Reid, George L. (EDT)

ISBN 10: 0081028245 / ISBN 13: 9780081028247

Edité par Elsevier, 2020

A propos de cet article

N° de réf. du vendeur 35623009-n

Détails bibliographiques

• Titre: Specification of Drug Substances and Products : Development and Validation of Analytical Methods
• Éditeur: Elsevier
• Date de parution: 2020
• Langue: anglais
• ISBN à 10 chiffres: 0081028245
• ISBN à 13 chiffres: 9780081028247
• Reliure: Couverture souple
• Édition: 2ème Édition
• État de l'article: New

A propos de ce titre

Synopsis

Specification of Drug Substances and Products: Development and Validation of Analytical Methods, Second Edition, presents a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development, validation of analytical methods, and their application in practice. This thoroughly revised second edition covers topics not covered or not substantially covered in the first edition, including method development and validation in the clinical phase, method transfer, process analytical technology, analytical life cycle management, special challenges with generic drugs, genotoxic impurities, topical products, nasal sprays and inhalation products, and biotechnology products.

The book's authors have been carefully selected as former members of the ICH Expert Working Groups charged with developing the ICH guidelines, and/or subject-matter experts in the industry, academia and in government laboratories.

À propos des auteurs

Dr. Christopher Riley is the President of Riley and Rabel Consulting Services. He received a bachelor's degree in Pharmacy (1977) and PhD degree in Pharmaceutical Chemistry (1980) from the University of Bath, UK. He taught Pharmaceutical Chemistry, at the Universities of Florida (1983-6) and the University of Kansas (1986-94), and was a Vice President at DuPont Merck (1994-2001) and ALZA (a division of J&J) (2001-7). He has coauthored more than 140 book chapters and papers in peer-reviewed journals, as well as 5 books. He has extensive experience in CMC regulatory affairs and the development of all types of dosage forms.

Former Director of Business Development at Acceleration Laboratory Services, Incorporated. He has previously held scientific and senior management positions at The Upjohn Company, Marion Laboratories, Marion Merrell Dow, Hoechst Marion Roussel, Quintiles, Eli Lilly, Beckloff Associates, and PPD. He currently serves on a Small Molecule USP Expert Committee.